Inovio Pharmaceuticals (STU:GBM) Shares Outstanding (Basic Average): 69.10 Mil (As of Mar. 2026)


STU:GBM Inovio Pharmaceuticals Inc STU:GBM
48 GF Score
Price €0.95
GF Value €0.19
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Inovio Pharmaceuticals Shares Outstanding (Basic Average)?

Inovio Pharmaceuticals STU:GBM -0.16% 48 Shares Outstanding (Basic Average) is 69.10 Mil as of Mar. 2026. GuruFocus rates STU:GBM with a GF Score™ of 48/100 and a GF Value™ of €0.19 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Inovio Pharmaceuticals's average basic shares outstanding for the quarter that ended in Mar. 2026 was 69.10 Mil.


Inovio Pharmaceuticals  (STU:GBM) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Inovio Pharmaceuticals Shares Outstanding (Basic Average) Related Terms


Inovio Pharmaceuticals Shares Outstanding (Basic Average) Historical Data

* Premium members only.

The historical data trend for Inovio Pharmaceuticals's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inovio Pharmaceuticals Shares Outstanding (Basic Average) Chart

Inovio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.40 19.89 22.17 27.16 46.89

Inovio Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.61 38.83 52.17 62.03 69.10
STU:GBM
48GF Score
Inovio Pharmaceuticals Inc STU:GBM
Shares Outstanding (Basic Average) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inovio Pharmaceuticals Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Basic Average) of 69.10 Mil mean?
Inovio Pharmaceuticals (STU:GBM) has a Shares Outstanding (Basic Average) of 69.10 Mil as of Mar. 2026. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Inovio Pharmaceuticals and its competitors.
Is Inovio Pharmaceuticals' Shares Outstanding (Basic Average) too high?
Inovio Pharmaceuticals' current Shares Outstanding (Basic Average) is 69.10 Mil. Overall, Inovio Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inovio Pharmaceuticals' Shares Outstanding (Basic Average) compare to OTLK and RANI?
Inovio Pharmaceuticals' Shares Outstanding (Basic Average) of 69.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Biotechnology company?
A good Shares Outstanding (Basic Average) depends on the Biotechnology industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Inovio Pharmaceuticals and its competitors. Inovio Pharmaceuticals's current Shares Outstanding (Basic Average) is 69.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inovio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Inovio Pharmaceuticals (STU:GBM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.19, compared to a current price of €0.95 — trading 398.7% above its estimated fair value. The current Shares Outstanding (Basic Average) is 69.10 Mil. Inovio Pharmaceuticals' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For Inovio Pharmaceuticals (STU:GBM), the current Shares Outstanding (Basic Average) is 69.10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inovio Pharmaceuticals (STU:GBM) Overvalued in 2026?

Based on GuruFocus' analysis, Inovio Pharmaceuticals stock appears to be overvalued. The current stock price of €0.95 is trading 398.7% above its estimated GF Value™ of €0.19. GuruFocus considers Inovio Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:GBM:

  • Shares Outstanding (Basic Average): 69.10 Mil
  • GF Value™: €0.19 vs. price of €0.95 (398.7% above fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the STU:GBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Inovio Pharmaceuticals Business Description

Other Exchanges INO:USAINO:Mexico0A43:UK
Address 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
48GF Score

Get the complete analysis for STU:GBM

Shares Outstanding (Basic Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.95
Price
€0.19
GF Value